ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MOLN / news
CRDL (44) CHRS (29) CMPX (34) TARA (32) ⌘ Pro Terminal →

Why MOLN Stock dropped -2.79% Today — RQD Quant Desk Flash

$3.48 -2.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.46

Molecular Partners AG (MOLN) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $134.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MOLN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MOLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Molecular Partners AG (NASDAQ: MOLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $3.48 (-2.79% 1D, market cap $134.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MOLN ranks #338 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MOLN compare to CRDL and CHRS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MOLN carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRDL (Cardiol Therapeutics Inc. (Class A)) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $133.9M) and CHRS (Coherus Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M). Among the 5-stock peer group, MOLN leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MOLN?
▼

For Molecular Partners AG (MOLN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #338 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.46 (-0.69%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.5% Base Target
$6 Bull$3 Base$3 Bear
📬 FREE MOLN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MOLN)Realized 20D OHLCV Swing Band: ±7.1%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY MOLN SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$3.79-3.4% Next Q
Q2 (-2Q)
51
Grade C-$3.66-1.9% Next Q
Q3 (-1Q)
49
Grade D$3.59-3.1% Next Q
Current
46
Grade D$3.48-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MOLN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MOLN currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.99) and Max Pain ($3.65) forces dealer call-delta covering toward $5.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MOLN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MOLN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MOLN Stock dropped -2.79% Today — RQD Quant Desk Flash

Molecular Partners AG (MOLN) dropped -2.79% to $3.48, trading at 2% of its 52-week range ($3.51 – $5.36). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($3.51 – $5.36) with RSI-14 at 41.5 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±7.1% around $3.48 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $3.8M annual free cash flow.
Live MOLN Headlines & Catalysts
CATALYSTBenzinga • 5d ago
Molecular Partners Q3 EPS $(0.38) Beats $(0.46) Estimate

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 76.97 percent increase over losses of $(1.65) per share

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MOLN)

  • ✓Walkthrough of MOLN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MOLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.09%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.53H $3.58L $3.48C $3.48VOL 1.8K
RES: $4.86SUP: $3.45SMA50: $3.99SMA200: $4.17
$4.81$4.45$4.09$3.73$3.37RES $4.86SUP $3.45$3.482026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MOLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MOLN Butterfly Map → + Track MOLN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MOLN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MOLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MOLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MOLN)

Health Care Rank #338 of 1015 ⚔️ CRDL vs MOLN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MOLN vs. CRDL, CHRS, CMPX, TARA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Molecular Partners AG (MOLN) ranks #338 by composite RQD confidence (46/100, grade D) and #617 by equity capitalization ($134.3M). Within this direct 5-issuer industry benchmark cohort, MOLN leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. MOLN currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MOLN ACTIVE
Molecular Partners AG
D 46/100 — — — -2.79% $134.3M Benchmark Subject
CRDL
Cardiol Therapeutics Inc. (Class A)
D 44/100 — — — -6.31% $133.9M /crdl-vs-moln →
CHRS
Coherus Oncology Inc.
E 29/100 — — -35.0% -9.72% $128.3M /chrs-vs-moln →
CMPX
Compass Therapeutics Inc.
E 34/100 — — -34.6% -2.42% $141.6M /cmpx-vs-moln →
TARA
Protara Therapeutics Inc.
E 32/100 — — -34.7% -2.82% $146.6M /tara-vs-moln →

2. MOLN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Molecular Partners AG (MOLN) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $134.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MOLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MOLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Molecular Partners AG (NASDAQ: MOLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $3.48 (-2.79% 1D, market cap $134.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MOLN ranks #338 in composite RQD confidence.

How does MOLN compare to CRDL and CHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MOLN carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRDL (Cardiol Therapeutics Inc. (Class A)) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $133.9M) and CHRS (Coherus Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M). Among the 5-stock peer group, MOLN leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MOLN?

For Molecular Partners AG (MOLN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #338 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MOLN trading relative to its 50-day, 200-day, and 52-week technical levels?

MOLN last traded at $3.48 (-2.79% on volume of 572 shares), positioning the stock -12.78% below its 50-day simple moving average ($3.99) and -16.55% below its 200-day simple moving average ($4.17). Across its 52-week range of $3.51 to $5.36, MOLN sits at the 0.0% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±7.1% ($3.23 to $3.73).

Direct Sub-Reports: MOLN RQD Cockpit MOLN 12M Forecast MOLN Earnings & Move MOLN Dividends & DRIP MOLN Insiders & 13F MOLN Whale Options MOLN Profit Sankey MOLN News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

MOLN — Molecular Partners AG: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Molecular Partners AG (MOLN) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $3.48 (-2.79% 1D, market capitalization $134.3M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Molecular Partners AG (MOLN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The market capitalization is $0.1B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.51 – $5.36 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The workforce reduction and radiopharmaceutical pivot described in the news feed are the only observable operational shifts in the data.

  • Key Question #1: Can MOLN sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $5.36 52-week high?
  • Key Question #3: How sensitive is MOLN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MOLN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Molecular Partners AG (MOLN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MOLN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MOLN Bull vs. Bear Conversation Board — What's Your Call at $3.48?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MOLN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MOLN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $4.12 (+15.1%)
📌 Pinned Debate

Preclinical data showing sustained tumor uptake in mice for a radioactive cancer candidate, plus the MP0730 CD70 lead selection, point

Preclinical data showing sustained tumor uptake in mice for a radioactive cancer candidate, plus the MP0730 CD70 lead selection, point to a radiopharmaceutical pipeline with possible re-rating potential.. When you look under the hood at MOLN, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.36. My 12M target is $4.12.

EarningsSniper 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $3.58 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $2.72 (-24.0%)
Spot @ $3.58

The RQD rating scores 0% ROIC and 0% FCF yield alongside weak Whale and Insider pillars, while reports of cutting up to 44% of the work

Here is the bear case nobody on the bull side wants to address on MOLN: The RQD rating scores 0% ROIC and 0% FCF yield alongside weak Whale and Insider pillars, while reports of cutting up to 44% of the workforce signal restructuring pressure.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE